GlassScriptPhysician profile
Jamal A Razzack
NPI 1831192319
$13,373.80
in general payments reported to CMS, 2019-2025
43 companies · $2,007 in 2025
The $2,007 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $808 · 2021: $1,517 · 2022: $4,020 · 2023: $1,698 · 2024: $2,376 · 2025: $2,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,042 · Travel and Lodging: $1,022 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,042.41 |
| Travel and Lodging | $1,021.96 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $3,024.74 | 2019-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Inspire Medical Systems, INC. | $1,871.37 | 2022-2025 | Inspire |
| Glaxosmithkline, LLC. | $1,391.01 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,059.83 | 2020-2025 | Tezspire, Airsupra, Breztri |
| Electromed, INC. | $864.62 | 2019-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $570.81 | 2019-2025 | Ofev, Stiolto Respimat |
| Insmed, INC. | $499.28 | 2019-2025 | Arikayce |
| Philips North America LLC | $441.75 | 2020-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Mylan Specialty L.P. | $431.35 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $261.37 | 2020-2025 | Uptravi, Opsumit, Opsynvi |
| Sunovion Pharmaceuticals INC. | $256.31 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $251.50 | 2020-2022 | |
| Genzyme Corporation | $217.62 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $190.91 | 2020-2023 | Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $177.33 | 2021-2025 | Aralast, Glassia |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Razzack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.